达托霉素
利奈唑啉
替考拉宁
菌血症
抗菌剂
微生物学
重症监护医学
万古霉素
加药
感染性心内膜炎
治疗药物监测
医学
心内膜炎
抗药性
耐万古霉素肠球菌
抗生素耐药性
抗生素
生物
药品
内科学
细菌
金黄色葡萄球菌
药理学
遗传学
作者
Kelly A. Cairns,Andrew Udy,Trisha Peel,Iain J. Abbott,Michael Dooley,Anton Y. Peleg
摘要
Vancomycin-resistant enterococci (VRE) are common causes of bloodstream infections (BSIs) with high morbidity and mortality rates. They are pathogens of global concern with a limited treatment pipeline. Significant challenges exist in the management of VRE BSI, including drug dosing, the emergence of resistance, and the optimal treatment for persistent bacteremia and infective endocarditis. Therapeutic drug monitoring (TDM) for antimicrobial therapy is evolving for VRE-active agents; however, there are significant gaps in the literature for predicting antimicrobial efficacy for VRE BSIs. To date, TDM has the greatest evidence for predicting drug toxicity for the three main VRE-active antimicrobial agents daptomycin, linezolid, and teicoplanin. This article presents an overview of the treatment options for VRE BSIs, the role of antimicrobial dose optimization through TDM in supporting clinical infection management, and challenges and perspectives for the future.
科研通智能强力驱动
Strongly Powered by AbleSci AI